Rachel Rennard

Rachel Rennard has worked in the biotechnology industry since 2000. Rachel started their career as a Senior Associate Scientist at Biogen Idec, where they worked on developing and launching a new technology (antibody phage display). In 2008, they joined X-BODY Biosciences as the third employee to lead the development of a novel antibody discovery solution from scratch. In 2010, they moved to Merrimack Pharmaceuticals as a Senior Scientist and was promoted in recognition of their scientific and organizational contributions. In 2014, Rachel was hired as a Principal Researcher at Moderna Therapeutics to build an in-house antibody discovery platform. In 2016, they became the Head of Antibody Discovery and Engineering at Compass Therapeutics and was responsible for discovering and optimizing antibodies against 50 therapeutic targets. In 2020, Rachel joined Alloy Therapeutics, Inc. as the CTO, Antibody Discovery & Head of Alloy Discovery Services. Rachel was an executive leader of a talented team of scientists working together to continuously evolve and leverage a novel antibody platform. In 2023, Rachel was appointed as the VP of Antibody Discovery and Optimization at Mosaic Biosciences.

Rachel Rennard obtained their Master's Degree in Molecular Genetics from The Ohio State University in 1997. Rachel then obtained their PsyD in Organizational and Leadership Psychology from William James College between 2016 and 2020. Prior to that, they obtained their Bachelor's Degree from The University of Texas at Austin in 1993. In addition, they obtained Advanced Training in Conflict Management in December 2015, and Foundations in Structural Dynamics: Making Change Happen in November 2015.